Get the Stockscreener App
16.31
0.12%
0.02
After Hours:
16.01
-0.30
-1.84%
10 X Genomics Inc stock is traded at $16.31, with a volume of 1.58M.
It is up +0.12% in the last 24 hours and down -13.29% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$16.29
Open:
$16.16
24h Volume:
1.58M
Relative Volume:
0.60
Market Cap:
$2.06B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-8.0743
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-2.28%
1M Performance:
-13.29%
6M Performance:
+40.85%
1Y Performance:
+13.58%
1-Day Range:
$16.00
$16.48
1-Week Range:
$15.91
$16.73
52-Week Range:
$6.78
$20.34
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
16.31 | 2.06B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
223.23 | 36.93B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
59.05 | 10.74B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
44.28 | 8.39B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.61 | 7.90B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
37.45 | 6.79B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
S P Trends: How dovish Fed policy supports 10x Genomics Inc 1KJ stockMarket Sentiment Review & Weekly Watchlist of Top Performers - moha.gov.vn
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
10x Genomics' Products Are Well-Received, But US Spending Weakness Stifles Growth (NASDAQ:TXG) - Seeking Alpha
Osaic Holdings Inc. Has $1.89 Million Stock Position in 10x Genomics $TXG - MarketBeat
Assenagon Asset Management S.A. Sells 1,696,984 Shares of 10x Genomics $TXG - MarketBeat
Friedenthal Financial Purchases New Holdings in 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Trading Down 4.1%Should You Sell? - MarketBeat
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending - Finviz
Barclays turns more bullish on 10x Genomics, Inc. (TXG) despite uneven research spending - MSN
Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - Nasdaq
10x Genomics (TXG) Stock Trades Up, Here Is Why - Finviz
10x Genomics (TXG) Maintains Buy Rating, Price Target Raised to $20 | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Canaccord Genuity Group - MarketBeat
Why 10x Genomics Inc. stock could outperform in 20252025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
How 10x Genomics Inc. stock responds to policy changesWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
Aug Swings: Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumQuarterly Trade Summary & AI Driven Stock Movement Reports - Улправда
Price Action: Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Is 10x Genomics Inc. (1KJ) stock attractive for growth fundsJuly 2025 Movers & Free High Accuracy Swing Entry Alerts - Улправда
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Panic Selling: How 10x Genomics Inc. stock responds to policy changesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - Улправда
Lancaster Investment Management Purchases Shares of 621,779 10x Genomics $TXG - MarketBeat
How 10x Genomics Inc. stock benefits from strong dollarWeekly Stock Summary & Comprehensive Market Scan Insights - DonanımHaber
Is 10x Genomics Inc. stock oversold or undervaluedJuly 2025 Recap & Daily Oversold Bounce Ideas - DonanımHaber
Why 10x Genomics Inc. stock could benefit from AI revolutionEntry Point & Short-Term Trading Alerts - Улправда
Is 10x Genomics Inc. stock a safe haven assetQuarterly Performance Summary & Technical Confirmation Alerts - DonanımHaber
History Review: Why 10x Genomics Inc. stock could outperform in 2025 - Улправда
Aug Rallies: Can 10x Genomics Inc. stock weather global recession2025 Winners & Losers & Low Risk High Reward Ideas - Улправда
Can 10x Genomics Inc. stock weather global recessionMarket Activity Report & Growth Focused Investment Plans - Улправда
Bear Alert: Why 10x Genomics Inc. stock could benefit from AI revolutionQuarterly Earnings Summary & Weekly Chart Analysis and Guides - Улправда
Setup Watch: Is 10x Genomics Inc. stock safe for conservative investors2025 Major Catalysts & Weekly Top Gainers Trade List - Улправда
Market Fear: How 10x Genomics Inc. stock responds to policy changesShare Buyback & Low Risk Growth Stock Ideas - Улправда
Barclays Maintains 10x Genomics (TXG) Overweight Recommendation - Nasdaq
Caxton Associates LLP Sells 259,388 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
10x Genomics $TXG Position Increased by Nikko Asset Management Americas Inc. - MarketBeat
Why The Narrative Around 10x Genomics Is Shifting After New Institutional Buying And Product Updates - Yahoo Finance
Bellevue Group AG Buys 95,754 Shares of 10x Genomics $TXG - MarketBeat
Federated Hermes Inc. Has $9.12 Million Holdings in 10x Genomics $TXG - MarketBeat
Why 10x Genomics (TXG) stock is nosediving - MSN
TXG: Citigroup Downgrades 10x Genomics to Neutral with $18 Price Target | TXG Stock News - GuruFocus
10x Genomics (TXG) Q2 2025 Earnings Transcript - The Motley Fool
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off - ts2.tech
Why 10x Genomics (TXG) Stock Is Nosediving - Finviz
10x Genomics' (TXG) Neutral Rating Reaffirmed at Citigroup - MarketBeat
Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
Blue Water Life Science Advisors LP Buys New Holdings in 10x Genomics $TXG - MarketBeat
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
10x Genomics (TXG) Is Down 5.5% After Morgan Stanley Downgrade Has The Bull Case Changed? - simplywall.st
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.51%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):